Three Arch Partners III LP
CIK 0001256741 Name as filed on the most recent filing
Filed as Three Arch Partners III LP (8)
19 transaction lines · from 8 filings · filed 2005-02-10 to 2014-11-20 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Concert Pharmaceuticals, Inc. 2 filings
- ISSUER Acelrx Pharmaceuticals Inc 4 filings
- ISSUER Threshold Pharmaceuticals Inc 2 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2014-11-18 |
Concert Pharmaceuticals, Inc. CNCE |
S, Open-market sale | 237,245 disposed | 12.29 | 2,915,741.05 | Form 4, filing 0001181431-14-036962 | |
| 2014-11-18 |
Concert Pharmaceuticals, Inc. CNCE |
S, Open-market sale | 12,755 disposed | 12.29 | 156,758.95 | Form 4, filing 0001181431-14-036962 | |
| 2014-02-19 |
Concert Pharmaceuticals, Inc. CNCE |
P, Open-market purchase | 98,219 acquired | 14.00 | 1,375,066.00 | Form 4, filing 0001209191-14-012993 | |
| 2014-02-19 |
Concert Pharmaceuticals, Inc. CNCE |
P, Open-market purchase | 5,281 acquired | 14.00 | 73,934.00 | Form 4, filing 0001209191-14-012993 | |
| 2012-12-07 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 2,364,705 acquired | 3.31 | 7,827,173.55 | Form 4, filing 0001181431-12-063710 | |
| 2012-12-07 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 52,213 acquired | 3.31 | 172,825.03 | Form 4, filing 0001181431-12-063710 | |
| 2012-05-29 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 67,543 acquired | 3.40 | 229,646.20 | Form 4, filing 0001181431-12-035046 | |
| 2012-05-29 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 208,911 acquired | 3.40 | 710,297.40 | Form 4, filing 0001181431-12-035046 | |
| 2012-05-29 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 3,631 acquired | 3.40 | 12,345.40 | Form 4, filing 0001181431-12-035046 | |
| 2012-05-29 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 4,613 acquired | 3.40 | 15,684.20 | Form 4, filing 0001181431-12-035046 | |
| 2012-05-29 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 208,911 acquired | 3.40 | 710,297.40 | Form 4, filing 0001181431-12-033676 | |
| 2012-05-29 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 67,543 acquired | 3.40 | 229,646.20 | Form 4, filing 0001181431-12-033676 | |
| 2012-05-29 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 4,613 acquired | 3.40 | 15,684.20 | Form 4, filing 0001181431-12-033676 | |
| 2012-05-29 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 3,631 acquired | 3.40 | 12,345.40 | Form 4, filing 0001181431-12-033676 | |
| 2011-02-16 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 1,223,983 acquired | 5.00 | 6,119,915.00 | Form 4, filing 0001181431-11-011588 | |
| 2011-02-16 |
Acelrx Pharmaceuticals Inc ACRX |
P, Open-market purchase | 65,806 acquired | 5.00 | 329,030.00 | Form 4, filing 0001181431-11-011588 | |
| 2006-03-03 |
Threshold Pharmaceuticals Inc THLD |
S, Open-market sale | 1,000,000 disposed | 14.50 | 14,500,000.00 | Form 4, filing 0001104659-06-014680 | |
| 2005-02-09 |
Threshold Pharmaceuticals Inc THLD |
P, Open-market purchase | 222,059 acquired | 7.00 | 1,554,413.00 | Form 4, filing 0001209191-05-008248 | |
| 2005-02-09 |
Threshold Pharmaceuticals Inc THLD |
P, Open-market purchase | 11,939 acquired | 7.00 | 83,573.00 | Form 4, filing 0001209191-05-008248 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. THREE ARCH PARTNERS III LP, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001256741
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6